Gland Pharma Limited — Q4 FY26
Gland Pharma reported a strong Q4 FY26 with consolidated revenue of INR 17,428 million (+22% YoY) and adjusted EBITDA margin of 30% (+500bps YoY), driven by robust CDMO growth (...
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY26
Cenexi annualized revenue run-rate of EUR 200M
Cenexi expected to maintain EUR 50 million quarterly run-rate on an annualized basis, with positive EBITDA trajectory.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1